Clinical Trial Search

Primary: Change From Baseline in Glycemic Coefficient of Variation (CV) in Treatment Period 1 — -0.69; 0.24 Percentage of CV

Primary: Derived Disease Assessment Based on Local Morphology Including All On-Treatment Data (Safety Population, FLT3-ITD [+] Participants) — 63; 62; 3; 5 participants

Primary: Number of CD8+ Inflammatory Cells in Bronchial Biopsy Tissue. — 442.4; 427.1 CD8+ cells count

Primary: Concentrations of Antibodies Against Vaccine Pneumococcal Serotypes (Primary Immunization) — 6.52; 0.04; 6.54; 0.03 μg/mL

Primary: Complete Resolution of Labial Adhesion. — 21; 22 Participants — p=0.206

Primary: Patellar Flexion Measured as the Relative Angle Between the Femoral and Patellar Components of the Implant. — 29.6; 21.0 degrees

Primary: Number of Participants With Suspected Adverse Drug Reactions (ADRs) — 5 Participants

Primary: Change of Patient Rated Pruritus Score — -1.61; -1.50 score on a scale

Primary: Macrophage Activation, TNF-a — 6.1; 3.8; 2.6 ng/ml — p=0.05

Primary: The Primary End Point for This Study is a 50% Fluoxetine-related Reduction in the Number of Seizures With Associated Oxygen Desaturations Below 90% Compared With Placebo.

Primary: Endothelial Glycocalyx Thickness — 2.28 micrometer

Primary: Time From Randomisation to Inadequate Glycaemic Control and Need for Treatment Intensification — NA; 104.3; 106.7; 90.3 Weeks — p=<.0001

Primary: Number of Participants With Bladder or Rectal Injury — 0 Participants

Primary: Feasibility Primary Endpoint — 38 Participants

Primary: Number Of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 473; 531; 640; 6 participants